Company / Return on Assets (ROA)
Esperion Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-4.9%
FY2025
5-year range
-101.7% / -4.9%
FY2021-FY2025
Trend
+67.6%
vs FY2024
Sector context
#74 of 213
Health Care
What the data says
At -4.9%, Esperion Therapeutics, Inc.'s return on assets (roa) ranks #74 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -140.7% in FY2018 to -4.9% in FY2025.
Based on SEC 10-K filings.
-4.9% in FY2025 with a 5-year CAGR of +35.8%.
Improved from -101.7% to -4.9% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +89.4pp
- 5-Year Change
- +35.8pp
- 10-Year Change
- -
Sector benchmark
#74 of 213 in Health CareTop 35% of 213This company -4.9% Sector average -24.1%
▼
+79.8% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 67.6% year-over-year.
- Currently 19.3pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -4.9% | +67.6% |
| FY2024 | -15.0% | +85.2% |
| FY2023 | -101.7% | -7.9% |
| FY2022 | -94.2% | -33.6% |
| FY2021 | -70.5% | -73.5% |
| FY2020 | -40.6% | +10.3% |
| FY2019 | -45.3% | +67.8% |
| FY2018 | -140.7% | -134.1% |
| FY2017 | -60.1% | -96.5% |
| FY2016 | -30.6% | -81.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026